Bories, P., Jongen-Lavrencic, M., Griškevičius, L., Pabst, T., Leeuw, D. D., Huls, G. A., Boissel, N., Pigneux, A., Boettcher, S., Dymkowska, M., Andrieu, C., Fernandez, E., Baverel, P., Stavropoulou, V., Sanderson, M., Kirkin, V., Legenne, P., Subklewe, M. (2025). Phase 1/2 study of MP0533, a tetra-specific T cell engager (CD33 x CD123 x CD70 x CD3), in patients with relapsed/refractory AML or MDS/AML: Initial results from optimized treatment regimen including densified MP0533 dosing and adapted premedication. Blood. https://doi.org/10.1182/blood-2025-3419